CCCC · C4 Therapeutics, Inc. · Documents

$2.77 -0.12 (-4.15%) At close · Nov 12

Russell 2000 member Rebalance outlook locked

Market Cap

$363.75M

131.32M

Volume · Nov 12 4.97M Avg daily vol (3M) 2.53M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $35.95M up 1.0% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $8.47M down 24.6% 10-Q filed Nov 5, 2026 Latest results Cemsidomide enrollment on track; cash runway through 2028 8-K filed Nov 5, 2026

2026

Nov 9

Investor event

Simsidamide posts 53% response rate in refractory myeloma

C4 Therapeutics reported a 53% overall response rate at the highest simsidamide dose in 72 first-in-human patients. Enrollment is expected to finish in the first quarter of 2027, with combination data guided for mid-year 2027.

4 source passages

welcome to this next five-side chat with C4 Therapeutics. So we can start with the top-line summary, that in a first-in-human study, When we treated 72 patients with simsidamide plus dex, we have an overall response rate of 53% at the highest dose level we've guided that that study will be finished enrollment in the first quarter of 2027 We've guided to data mid-year 2027 from that study from all the cohorts that we've evaluated. Open the document at this passage

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Revenue $8.47M ▼ 24.6% Net loss $21.84M Diluted EPS -$0.16

Nov 5

Current report 8-K

Cemsidomide enrollment on track; cash runway through 2028

C4 Therapeutics expects cash to fund operations to the end of 2028, while cemsidomide’s Phase 2 MOMENTUM enrollment is on track to complete in the first quarter of 2027; third-quarter 2026 revenue was $8.5 million.

Financial results

4 source passages

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the third quarter ended September 30, 2026, as well as recent business highlights. The Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in late-line MM is on track to complete enrollment in the first quarter of 2027. Total revenue for the third quarter of 2026 was $8.5 million, compared to $11.2 million for the third quarter of 2025. C4T expects that its current cash, cash equivalents and marketable securities will fund its operating plan to the end of 2028. Open the document at this passage

Sep 25

Current report 8-K

Regulation FD disclosure, Other events

C4 Therapeutics reported cemsidomide immune activation in 62 RRMM patients and biomarker findings from two patients; the 75 µg dose was declared safe, and cohorts at 75 µg and 100 µg are advancing, with data expected in mid-2027.

Sep 10

Investor event

2026 Wells Fargo Healthcare Conference AI summary on its way

Aug 11

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $6.64M ▲ 2.8% Net loss $23.64M Diluted EPS -$0.18

Aug 11

Current report 8-K

Financial results AI summary on its way

Jun 24

Current report 8-K